Biognosys Supports Cancer Scout, a Large-Scale Multi-Omics Research Project to Accelerate Personalized Cancer Medicine
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it is supporting Cancer Scout as Proteomics provider.
Cancer Scout is a large-scale joint research project led by University Medical Center Göttingen and Siemens Healthineers. The project received funding of EUR 10 million by the German Federal Ministry of Education and Research (BMBF) 1.
The objective of Cancer Scout is to provide a new Artificial Intelligence tool for precision medicine in the fight against cancer. The research project will analyze and combine genomics, proteomics, and pathology data through Artificial Intelligence to generate a "digital biopsy" of molecular changes in tumors. Identifying these molecular changes can support early and accurate cancer diagnosis and predict personalized therapies for a patient’s tumor.
Oliver Rinner, PhD, CEO and founder of Biognosys states: “We are excited to be part of this visionary multi-omics research project and contribute to the development of more personalized clinical diagnostics and therapies for cancer with our proteomics solutions.”
Biognosys was selected as the provider for the Proteomics data analysis in Cancer Scout, based on its unique technologies and workflows for large-scale proteomics, comprehensive quality standards for clinical research, and extensive expertise in precision oncology.
Biognosys’ discovery proteomics platform utilizes proprietary, patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology to quantify complete proteomes with unmatched precision, depth, and reproducibility. This solution can be applied with high throughput in large-scale studies involving thousands of samples from a broad range of clinical sample types.
Professor Philipp Ströbel, Director of Pathology at the University Hospital Göttingen, comments: “Combining digital pathology with proteomics and other omics data is essential to identify the full spectrum of molecular changes in tumors and enable truly personalized cancer care.”
Christian Wolfrum, Head of New Business Development and Planning at Siemens Healthineers, adds: “We are excited to work with Biognosys to generate novel scientific insights in Cancer Scout and translate these into personalized cancer care solutions for clinical practice.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About University Hospital Göttingen
The University Medical Center Göttingen (UMG) is one of the leading university medical facilities in Germany. For more information, please visit https://www.umg.eu/en/.
About Siemens Healthineers
To learn more about Siemens Healthineers, please visit siemens-healthineers.com.
1 Funding reference number FKZ 13GW0451A+B
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005036/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Partners with Shopify to Reimagine Digital Beauty Commerce and Elevate Consumer Experiences28.10.2025 23:26:00 EET | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a strategic partnership with Shopify Inc., a leading global commerce platform, to modernize its digital technology infrastructure and deliver best-in-class omnichannel consumer experiences. This collaboration will establish a new digital commerce foundation aimed at increasing consumer centricity, fueling sustainable growth, and driving speed and efficiencies at scale across The Estée Lauder Companies’ diverse portfolio of prestige and luxury beauty brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028165887/en/ This breakthrough and first-of-its-kind omnichannel partnership is part of The Estée Lauder Companies’ Beauty Reimagined strategy, which focuses on reaching consumers in smarter, faster, and more personalized ways. Together, The Estée Lauder Companies and Shopify will innovate and co-develop a modern, unified commerce experience that leverages data and
1888 Studios and Paramount Announce Landmark 10-Year Lease Agreement to Unlock Access to Newly Enhanced Film and Television Tax Incentives28.10.2025 22:35:00 EET | Press release
1888 Studios, a state-of-the-art, 1.6 million square foot film and television production campus in Bayonne, NJ, to be built for movie makers by movie makers, announced today that Paramount, a Skydance Corporation, (“Paramount”) (NASDAQ: PSKY), a leading, next generation global media and entertainment company, has signed a landmark minimum 10-year lease agreement. Paramount has committed to occupy more than 285,000 square feet of the facility, establishing a major production hub in New Jersey. Paramount’s commitment further cements the state as a premier destination for film and television production, backed by a leading tax incentive program. Currently under development by Togus Urban Renewal, 1888 Studios is set to become the largest campus-style production facility in the Northeast and one of the largest in the nation. The 58-acre facility will offer over 1.1 million square feet of production space spanning 23 smart sound stages with a minimum of 40-foot clear ceilings; production su
SS&C Introduces AI Agents to Simplify Financial Services and Healthcare Operations28.10.2025 22:05:00 EET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the launch of its AI agent catalogue for financial services and healthcare firms. The outcome-focused AI agents are designed to simplify complex operations such as credit processing and contract validation. Delivered as a managed service, the agents help organizations overcome talent shortages and operational bottlenecks securely and at-scale. One of the first customers to evaluate an SS&C AI Agent is American Life, a rapidly growing carrier in the annuity and retirement space based in Lincoln, Nebraska. The firm is leveraging and evaluating SS&C’s Credit Agreement Document Agent to streamline processing within its private credit operations. The AI agent continuously reviews and updates lengthy loan documents, cutting time and errors associated with manual review. SS&C saw a significant reduction in credit processing times within internal operations by using the technology. “SS&C’s AI agent offering stood out due to its su
Logitech Announces Q2 Fiscal Year 2026 Results28.10.2025 22:05:00 EET | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the second quarter of Fiscal Year 2026. Sales were $1.19 billion, up 6 percent in US dollars and 4 percent in constant currency compared to Q2 of the prior year. GAAP gross margin was 43.4 percent, down 20 basis points compared to Q2 of the prior year. Non-GAAP gross margin was 43.8 percent, down 30 basis points compared to Q2 of the prior year. GAAP operating income was $191 million, up 19 percent compared to Q2 of the prior year. Non-GAAP operating income was $230 million, up 19 percent compared to Q2 of the prior year. GAAP earnings per share (EPS) was $1.15, up 21 percent compared to Q2 of the prior year. Non-GAAP EPS was $1.45, up 21 percent compared to Q2 of the prior year. Cash flow from operations was $229 million. The quarter-ending cash balance was $1.4 billion. The Company returned $340 million to shareholders through its ann
IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction28.10.2025 22:04:00 EET | Press release
IQM Quantum Computers, a global leader in superconducting quantum computers, today announced it will integrate NVIDIA’s NVQLink into its quantum computers to scale error correction, a key component for realising quantum computing applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028095798/en/ IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction NVQLink is an open and interoperable platform integrated with NVIDIA CUDA-Q that connects quantum hardware to AI supercomputing. It provides low-latency and high-throughput connectivity between quantum computers and Graphics Processing Unit (GPU)-accelerated compute, enabling the real-time orchestration of computational tasks needed for running useful hybrid quantum-classical applications and quantum error correction. While today’s quantum computers are reaching sizes that unlock algorithms in simulation, optimization, and machine learning,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom